Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit



JERUSALEM, October 6, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City.

Date:  Wednesday, October 11, 2017

Venue: Sofitel New York Hotel

Format:  One-on-One Meetings with Investors

Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma

The investor presentation will be posted to the Events section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com  

SOURCE Intec Pharma Ltd.


These press releases may also interest you

at 01:15
SANTA ROSA, Calif., Oct. 17, 2017 /PRNewswire/ -- Sutter Santa Rosa Regional Hospital announced today that it will reopen with full services at 7 a.m. on Tuesday, Oct. 17? just eight days after the hospital was evacuated during the devastating Tubbs...

16 oct 2017
COLUMBUS, Ga., Oct. 16, 2017 /PRNewswire/ -- Aflac Incorporated announced today that it has priced ¥60 billion (par value) in yen-denominated subordinated debentures with a coupon of 2.108%. The subordinated debentures will mature in 2047 and are...

16 oct 2017
LAVAL, Quebec, Oct. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant...

16 oct 2017
NEW YORK, Oct. 16, 2017 /PRNewswire-USNewswire/ -- Two renowned Parkinson's disease and movement disorders physician-researchers have been appointed co-executive directors of the Marlene and Paolo Fresco Institute for Parkinson's and Movement...

16 oct 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of...

16 oct 2017
LOS ANGELES, Oct. 16, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Nasdaq has granted the Company's request for a continued listing pending...




News published on 6 october 2017 at 07:00 and distributed by: